Literature DB >> 15071791

Hereditary elliptocytosis: spectrin and protein 4.1R.

Patrick G Gallagher1.   

Abstract

Hereditary elliptocytosis (HE) is a common disorder of erythrocyte shape, occurring especially in individuals of African and Mediterranean ancestry, presumably because elliptocytes confer some resistance to malaria. The principle lesion in HE is mechanical weakness or fragility of the erythrocyte membrane skeleton due to defects in alpha-spectrin, beta-spectrin, or protein 4.1. Numerous mutations have been described in the genes encoding these proteins, including point mutations, gene deletions and insertions, and mRNA processing defects. Several mutations have been identified in a number of individuals on the same genetic background, suggesting a "founder effect." The majority of HE patients are asymptomatic, but some may experience hemolytic anemia, splenomegaly, and intermittent jaundice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15071791     DOI: 10.1053/j.seminhematol.2004.01.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  50 in total

1.  New antimalarial indolone-N-oxides, generating radical species, destabilize the host cell membrane at early stages of Plasmodium falciparum growth: role of band 3 tyrosine phosphorylation.

Authors:  Antonella Pantaleo; Emanuela Ferru; Rosa Vono; Giuliana Giribaldi; Omar Lobina; Françoise Nepveu; Hany Ibrahim; Jean-Pierre Nallet; Franco Carta; Franca Mannu; Proto Pippia; Estela Campanella; Philip S Low; Francesco Turrini
Journal:  Free Radic Biol Med       Date:  2011-11-15       Impact factor: 7.376

Review 2.  Tropomodulins: pointed-end capping proteins that regulate actin filament architecture in diverse cell types.

Authors:  Sawako Yamashiro; David S Gokhin; Sumiko Kimura; Roberta B Nowak; Velia M Fowler
Journal:  Cytoskeleton (Hoboken)       Date:  2012-05-04

Review 3.  The spectrin-ankyrin-4.1-adducin membrane skeleton: adapting eukaryotic cells to the demands of animal life.

Authors:  Anthony J Baines
Journal:  Protoplasma       Date:  2010-07-29       Impact factor: 3.356

4.  A comprehensive model of the spectrin divalent tetramer binding region deduced using homology modeling and chemical cross-linking of a mini-spectrin.

Authors:  Donghai Li; Sandra L Harper; Hsin-Yao Tang; Yelena Maksimova; Patrick G Gallagher; David W Speicher
Journal:  J Biol Chem       Date:  2010-07-06       Impact factor: 5.157

5.  Mutadelic: mutation analysis using description logic inferencing capabilities.

Authors:  Matthew E Holford; Michael Krauthammer
Journal:  Bioinformatics       Date:  2015-08-12       Impact factor: 6.937

6.  A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred.

Authors:  Daniel B Costa; Larisa Lozovatsky; Patrick G Gallagher; Bernard G Forget
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

7.  DNA methylation in promoter regions of red cell membrane protein genes in healthy individuals and patients with hereditary membrane disorders.

Authors:  Ralph Remus; Akio Kanzaki; Ayumi Yawata; Hidekazu Nakanishi; Hideho Wada; Takashi Sugihara; Michael Zeschnigk; Ines Zuther; Birgit Schmitz; Frauke Naumann; Walter Doerfler; Yoshihito Yawata
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

8.  Modelling and rapid simulation of multiple red blood cell light scattering.

Authors:  T I Zohdi; F A Kuypers
Journal:  J R Soc Interface       Date:  2006-12-22       Impact factor: 4.118

9.  Cytoskeletal dynamics of human erythrocyte.

Authors:  Ju Li; George Lykotrafitis; Ming Dao; Subra Suresh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-12       Impact factor: 11.205

10.  Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis.

Authors:  Omar Niss; Satheesh Chonat; Neha Dagaonkar; Marya O Almansoori; Karol Kerr; Zora R Rogers; Patrick T McGann; Maa-Ohui Quarmyne; Mary Risinger; Kejian Zhang; Theodosia A Kalfa
Journal:  Blood Cells Mol Dis       Date:  2016-07-17       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.